febuxostat has been researched along with Edema, Pulmonary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, AAE; Ahmed, MAE; El Morsy, EM | 1 |
| Fahmi, AN; Salem, HA; Shebl, AM; Shehatou, GS | 1 |
2 other study(ies) available for febuxostat and Edema, Pulmonary
| Article | Year |
|---|---|
Protective effects of febuxostat against paraquat-induced lung toxicity in rats: Impact on RAGE/PI3K/Akt pathway and downstream inflammatory cascades.
Topics: Acute Lung Injury; Animals; beta Catenin; Febuxostat; Inflammation; Lung; Lung Injury; Male; Oxidative Stress; Paraquat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pulmonary Edema; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Xanthine Oxidase | 2019 |
Febuxostat protects rats against lipopolysaccharide-induced lung inflammation in a dose-dependent manner.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; C-Reactive Protein; Dose-Response Relationship, Drug; Febuxostat; Glutathione; L-Lactate Dehydrogenase; Leukocyte Count; Lipopolysaccharides; Lung; Male; Malondialdehyde; Nitric Oxide; Pulmonary Edema; Rats, Sprague-Dawley; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Xanthine Oxidase | 2016 |